Patrolling Alveolar Macrophages Conceal Bacteria from the Immune System to Maintain Homeostasis

Cell. 2020 Oct 1;183(1):110-125.e11. doi: 10.1016/j.cell.2020.08.020. Epub 2020 Sep 3.

Abstract

During respiration, humans breathe in more than 10,000 liters of non-sterile air daily, allowing some pathogens access to alveoli. Interestingly, alveoli outnumber alveolar macrophages (AMs), which favors alveoli devoid of AMs. If AMs, like most tissue macrophages, are sessile, then this numerical advantage would be exploited by pathogens unless neutrophils from the blood stream intervened. However, this would translate to omnipresent persistent inflammation. Developing in vivo real-time intravital imaging of alveoli revealed AMs crawling in and between alveoli using the pores of Kohn. Importantly, these macrophages sensed, chemotaxed, and, with high efficiency, phagocytosed inhaled bacterial pathogens such as P. aeruginosa and S. aureus, cloaking the bacteria from neutrophils. Impairing AM chemotaxis toward bacteria induced superfluous neutrophil recruitment, leading to inappropriate inflammation and injury. In a disease context, influenza A virus infection impaired AM crawling via the type II interferon signaling pathway, and this greatly increased secondary bacterial co-infection.

Keywords: alveolar macrophages; alveoli; cell migration; chemotaxis; influenza; intravital microscopy; lung inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacteria / immunology*
  • Female
  • Homeostasis
  • Humans
  • Lung / immunology
  • Lung / metabolism
  • Macrophages / immunology
  • Macrophages / metabolism
  • Macrophages, Alveolar / immunology*
  • Macrophages, Alveolar / metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neutrophil Infiltration
  • Neutrophils / immunology
  • Phagocytosis / immunology
  • Pseudomonas aeruginosa / immunology
  • Pseudomonas aeruginosa / pathogenicity
  • Pulmonary Alveoli
  • Signal Transduction
  • Staphylococcus aureus / immunology
  • Staphylococcus aureus / pathogenicity

Grants and funding